Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

By sjmartinez • October 16, 2023

Iannone V, Babu AF, Lok J, Gómez-Gallego C, D'Auria G, Vazquez-Uribe R, Vaaben TH, Bongers M, Mikkonen S, Vaittinen M, Tikkanen I, Kettunen M, Klåvus A, Sehgal R, Kaminska D, Pihlajamaki J, Hanhineva K, El-Nezami H, Alexander Sommer MO, Kolehmainen M. Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model. Mol Metab. 2023 Oct 13:101823. doi: 10.1016/j.molmet.2023.101823. Epub ahead of print. PMID: 37839774.

Tags: aldafermin, Cardiology/Epi, genetically modified E. coli Nissle 1917, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, non-targeted metabolomics, omics integration, Publications, Transcriptomics

Prognostic implications of heart failure stages among Chinese community populations: insight from a nationwide population-based study

Zheng C, Cai A, Wang X, Qiu J, Song Q, Gu R, Cao X, Tian Y, Hu Z, Fonarow GC, Lip GYH, Wang Z, Feng[...]

A (cholesterol) crystal clear path to inflammasome activation in atherosclerosis

Li X, Sallam T. A (cholesterol) crystal clear path to inflammasome activation in atherosclerosis. J Lipid Res. 2024 May 3:100554. doi: 10.1016/j.jlr.2024.100554. Epub ahead of[...]

Generalizability of PGS313 for breast cancer risk in a Los Angeles biobank

Shang H, Ding Y, Venkateswaran V, Boulier K, Kathuria-Prakash N, Malidarreh PB, Luber JM, Pasaniuc B. Generalizability of PGS313 for breast cancer risk in a Los[...]